The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Open accessAbstract
Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Murphy, G. J., Reeves, B. C., Rogers, C. A., Rizvi, S. I. A., Culliford, L., & Angelini, G. D. (2007) · Circulation · doi:10.1161/circulationaha.107.698977 · Cited by 1,371
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Carson, J. L., Stanworth, S. J., Roubinian, N., Fergusson, D. A., Triulzi, D., Doree, C., & Hebert, P. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002042.pub4 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Self-citationLudwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Self-citationJaime, J., Salas, M., Ward, A., & Goss, G. D. (2001) · PubMed · Cited by 844
Caro, J. J., Salas, M., Ward, A., & Goss, G. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2214::aid-cncr1251>3.0.co;2-p · Cited by 764
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Self-citationLeyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Body iron metabolism and pathophysiology of iron overload
Kohgo, Y., Ikuta, K., Ohtake, T., Torimoto, Y., & Kato, J. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0120-5 · Cited by 616
Rohde, J. M., Dimcheff, D. E., Blumberg, N., Saint, S., Langa, K. M., Kuhn, L., Hickner, A., & Rogers, M. A. M. (2014) · JAMA · doi:10.1001/jama.2014.2726 · Cited by 613
Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2875 · Cited by 595
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation
Wish, J. B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01490506 · Cited by 556
Goodnough, L. T., Maniatis, A., Earnshaw, P., Benoni, G., Beris, P., Bisbe, E., Fergusson, D. A., Gombotz, H., Habler, O., Monk, T. G., et al. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aeq361 · Cited by 543
Labile iron pool: the main determinant of cellular response to oxidative stress
Kruszewski, M. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.004 · Cited by 533
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
Mandalà, M., Falanga, A., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr392 · Cited by 512
Vansteenkiste, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1211 · Cited by 477
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04153.x · Cited by 458
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Carson, J. L., Carless, P. A., & Hebert, P. C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002042.pub3 · Cited by 442
Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P., Demetri, G. D., Sarokhan, B. J., Slavin, M. B., & Glaspy, J. A. (2002) · Cancer · doi:10.1002/cncr.10763 · Cited by 428
Self-citationWright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Holst, L. B., Petersen, M. W., Haase, N., Perner, A., & Wetterslev, J. (2015) · BMJ · doi:10.1136/bmj.h1354 · Cited by 426
Auerbach, M., Ballard, H., Trout, J. R., McIlwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L., & Rana, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.119 · Cited by 414
Perioperative blood transfusions for the recurrence of colorectal cancer
Amato, A., & Pescatori, M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005033 · Cited by 406
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
Bokemeyer, C., Aapro, M. S., Courdi, A., Foubert, J., Link, H., Österborg, A., Repetto, L., & Soubeyran, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.014 · Cited by 403
Self-citationErythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
Iron, hemochromatosis, and hepatocellular carcinoma
Kowdley, K. V. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.019 · Cited by 391
Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.-T., et al. (2008) · Blood · doi:10.1182/blood-2007-06-096370 · Cited by 334
Erythropoietin and erythropoietin receptor expression in human cancer.
Ács, G., Acs, P. I., Beckwith, S. M., Pitts, R. L., Clements, E. E., Wong, K., & Verma, A. M. (2001) · PubMed · Cited by 315
Biosimilars: the science of extrapolation
Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.-C., & Schneider, C. K. (2014) · Blood · doi:10.1182/blood-2014-06-583617 · Cited by 307
Anti-Epo receptor antibodies do not predict Epo receptor expression
Elliott, S., Busse, L., Bass, M. B., Lu, H., Sarosi, I., Sinclair, A. M., Spahr, C., Um, M., Van, G., & Begley, C. G. (2006) · Blood · doi:10.1182/blood-2005-10-4066 · Cited by 305
Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Evstatiev, R., & Gasche, C. (2012) · Gut · doi:10.1136/gut.2010.214312 · Cited by 293
Baek, J. H., D’Agnillo, F., Vallelian, F., Pereira, C. P., Williams, M. C., Jia, Y., Schaer, D. J., & Buehler, P. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59770 · Cited by 280
Henry, D. H., Dahl, N. V., Auerbach, M., Tchekmedyian, S., & Laufman, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-231 · Cited by 264
Salpeter, S. R., Buckley, J. S., & Chatterjee, S. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.09.017 · Cited by 262
Ludwig, H., Müldür, E., Endler, G., & Hübl, W. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt118 · Cited by 259
Self-citationCella, D., Kallich, J., McDermott, A., & Xu, X. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh235 · Cited by 246
Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
Henke, M., Mattern, D., Pepe, M., Bézay, C., Weissenberger, C., Werner, M., & Pajonk, F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2737 · Cited by 240
Glaspy, J., Crawford, J., Vansteenkiste, J., Henry, D., Rao, S., Bowers, P., Berlin, J. A., Tomita, D., Bridges, K., & Ludwig, H. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605498 · Cited by 237
Self-citationLenalidomide and Venous Thrombosis in Multiple Myeloma
(2006) · New England Journal of Medicine · doi:10.1056/nejmc053530 · Cited by 232
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0055 · Cited by 226
Smith, R. E., Aapro, M. S., Ludwig, H., Pintér, T., Šmakal, M., Ciuleanu, T. E., Chen, L., Lillie, T., & Glaspy, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2885 · Cited by 211
Self-citationGreenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M. L., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211797 · Cited by 208
Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., et al. (2010) · Blood · doi:10.1182/blood-2010-08-300541 · Cited by 208
Hedenus, M., Birgegård, G., Näsman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Lärfars, G., & Österborg, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404562 · Cited by 198
Self-citationAapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y. (2012) · Annals of Oncology · doi:10.1093/annonc/mds112 · Cited by 196
Self-citationBastit, L., Vandebroek, A., Altintas, S., Gaede, B., Pintér, T., Suto, T. S., Mossman, T. W., Smith, K. E., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4620 · Cited by 195
Adverse Blood Transfusion Outcomes: Establishing Causation
Isbister, J. P., Shander, A., Spahn, D. R., Erhard, J., Farmer, S. L., & Hofmann, A. (2011) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2010.11.001 · Cited by 191
Self-citationThe AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine
Callum, J. L., Waters, J. H., Shaz, B. H., Sloan, S. R., & Murphy, M. F. (2014) · Transfusion · doi:10.1111/trf.12802 · Cited by 188
Iron and Colorectal Cancer Risk: Human Studies
Nelson, R. L. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2001.tb07002.x · Cited by 181
Aapro, M. S., & Link, H. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s3-33 · Cited by 174
Self-citationMyelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P., Haase, D., Sanz, G. F., Santini, V., & Buske, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu180 · Cited by 170
Self-citationThe erythropoietin receptor in normal and cancer tissues
JELKMANN, W. E. B., Bohlius, J., Hallek, M. J., & Sytkowski, A. J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.006 · Cited by 168
Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2051 · Cited by 168
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M. J., Weingart, O., Kluge, S., et al. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007303.pub2 · Cited by 167
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, L. K., Bering, H., Carson, K. R., Kleinerman, J., Kukreti, V., Ma, A., Mueller, B. U., O'Brien, S. H., Pasquini, M., Sarode, R., et al. (2013) · Blood · doi:10.1182/blood-2013-07-518423 · Cited by 166
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
Schrijvers, D. M., Samblanx, H. D., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq202 · Cited by 160
Self-citationHofmann, A., Farmer, S. L., & Shander, A. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s3-3 · Cited by 145
Self-citationLudwig, H., Crawford, J., Österborg, A., Vansteenkiste, J., Henry, D. H., Fleishman, A. N., Bridges, K., & Glaspy, J. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1130 · Cited by 142
Self-citationMoyo, V. M., Lefèbvre, P., Duh, M. S., Yektashenas, B. H., & Mundle, S. D. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0450-7 · Cited by 140
Brugnara, C., Chambers, L., Malynn, E., Goldberg, M., & Kruskall, M. (1993) · Blood · doi:10.1182/blood.v81.4.956.956 · Cited by 139
Liang, K., Esteva, F. J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.-Y., Li, Y., Li, X., Chen, C.-T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.025 · Cited by 139
Aapro, M., JELKMANN, W. E. B., Constantinescu, S. N., & Leyland-Jones, B. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.42 · Cited by 128
Self-citationClinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
Santini, V., Alessandrino, P. E., Angelucci, E., Barosi, G., Billio, A., Maïo, M. D., Finelli, C., Locatelli, F., Marchetti, M., Morra, E., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.018 · Cited by 125
Self-citationHow to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Steensma, D. P., Sloan, J. A., Dakhil, S. R., Dalton, R. J., Kahanic, S. P., Prager, D. J., Stella, P. J., Rowland, K. M., Novotny, P. J., & Loprinzi, C. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3644 · Cited by 120
Pirker, R., Ramlau, R., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., & Vansteenkiste, J. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0748 · Cited by 114
Steinmetz, T., Tschechne, B., Harlin, O., Klement, B., Franzem, M., Wamhoff, J., Tesch, H., Rohrberg, R., & Marschner, N. W. (2012) · Annals of Oncology · doi:10.1093/annonc/mds338 · Cited by 113
Dangsuwan, P., & Manchana, T. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.12.004 · Cited by 112
Demetri, G. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1750 · Cited by 110
Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
Praditpornsilpa, K., Tiranathanagul, K., Kupatawintu, P., Jootar, S., Intragumtornchai, T., Tungsanga, K., Teerapornlertratt, T., Lumlertkul, D., Townamchai, N., Susantitaphong, P., et al. (2011) · Kidney International · doi:10.1038/ki.2011.68 · Cited by 107
Kim, Y. T., Kim, S. H., YOON, B., CHO, H., Nahm, E., Kim, S. H., Kim, J., & Kim, J. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.11.014 · Cited by 106
Quality of Original and Biosimilar Epoetin Products
Brinks, V., Hawe, A., Basmeleh, A., Joachin-Rodriguez, L., Haselberg, R., Somsen, G. W., Jiskoot, W., & Schellekens, H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0288-2 · Cited by 102
Predictors and costs of surgical site infections in patients with endometrial cancer
Bakkum-Gamez, J. N., Dowdy, S. C., Borah, B. J., Haas, L. R., Mariani, A., Martin, J. R., Weaver, A. L., McGree, M. E., Cliby, W. A., & Podratz, K. C. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.022 · Cited by 102
Expression and function of erythropoietin receptors in tumors
Sinclair, A. M., Todd, M. D., Forsythe, K., Knox, S. J., Elliott, S., & Begley, C. G. (2007) · Cancer · doi:10.1002/cncr.22832 · Cited by 99
Absence of functional EpoR expression in human tumor cell lines
Swift, S. E., Ellison, A. R., Kassner, P. D., McCaffery, I., Rossi, J. M., Sinclair, A. M., Begley, C. G., & Elliott, S. G. (2010) · Blood · doi:10.1182/blood-2009-10-248674 · Cited by 99
Do two intravenous iron sucrose preparations have the same efficacy?
Rottembourg, J. B., Kadri, A., Leonard, E., Dansaert, A., & Lafuma, A. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr024 · Cited by 95
Brown, W. M., Maxwell, P., Graham, A. N. J., Yakkundi, A., Dunlop, E. A., Shi, Z., Johnston, P. G., & Lappin, T. R. J. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0687 · Cited by 95
de Swart, L., Smith, A. G., Johnston, W. T., Haase, D. T., Droste, J., Fenaux, P., Symeonidis, A. S., Sanz, G. F., Hellström‐Lindberg, E., Čermák, J., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13450 · Cited by 94
Self-citationBlood transfusion and cancer surgery outcomes: A continued reason for concern
Al‐Refaie, W. B., Parsons, H. M., Markin, A., Abrams, J. H., & Habermann, E. B. (2012) · Surgery · doi:10.1016/j.surg.2012.06.008 · Cited by 93
Auerbach, M., Silberstein, P. T., Webb, R. T., Averyanova, S. V., Ciuleanu, T., Shao, J. Z., & Bridges, K. R. (2010) · American Journal of Hematology · doi:10.1002/ajh.21779 · Cited by 91
Erythropoietin Receptor Signaling through STAT3 Is Required for Glioma Stem Cell Maintenance
Cao, Y., Lathia, J. D., Eyler, C. E., Wu, Q., Li, Z., Wang, H., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2010) · Genes & Cancer · doi:10.1177/1947601909356352 · Cited by 90
Beguin, Y. P., Aapro, M., Ludwig, H., Mizzen, L., & Österborg, A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.10.008 · Cited by 89
Self-citationManagement of Anemia in Cancer Patients: Transfusions
Schrijvers, D. L. A. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s3-12 · Cited by 84
Self-citationHenry, D. H., Dahl, N. V., & Auerbach, M. (2011) · American Journal of Hematology · doi:10.1002/ajh.22262 · Cited by 83
Current Status of Pharmacologic Therapies in Patient Blood Management
Goodnough, L. T., & Shander, A. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318273f4ae · Cited by 83
Leyland-Jones, B. R., Bondarenko, I., Nemsadze, G., Smirnov, V., Litvin, I., Kokhreidze, I., Abshilava, L., Janjalia, M., Li, R., Lakshmaiah, K. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5649 · Cited by 83
Santini, V., Schemenau, J., Levis, A., Balleari, E., Sapena, R., Adès, L., Guerci‐Bresler, A., Beyne‐Rauzy, O., Gourin, M.-P., Chèze, S., et al. (2013) · Blood · doi:10.1182/blood-2013-07-512442 · Cited by 79
Self-citationWizemann, V., Rutkowski, B., Baldamus, C. A., Scigalla, P., & Koytchev, R. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273264 · Cited by 77
Hershman, D. L., Buono, D. L., Malin, J. L., McBride, R. B., Tsai, W. Y., & Neugut, A. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp387 · Cited by 74
Efficace, F., Gaïdano, G., Breccia, M., Criscuolo, M., Cottone, F., Caocci, G., Bowen, D., Lübbert, M., Angelucci, E., Stauder, R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13138 · Cited by 71
Self-citationÖsterborg, A., Aapro, M., Cornes, P., Haselbeck, A., Hayward, C. R. W., & JELKMANN, W. E. B. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.012 · Cited by 71
Self-citationRoss, S. D., Allen, I. E., Probst, C. A., Sercus, B., Crean, S. M., & Ranganathan, G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1264 · Cited by 70
Bohlius, J., Tonia, T., Nüesch, E., Jüni, P., Fey, M. F., Egger, M., & Bernhard, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.171 · Cited by 69
Elliott, S., Busse, L. A., McCaffery, I., Rossi, J., Sinclair, A. M., Spahr, C. S., Swift, S. E., & Begley, C. G. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.10.006 · Cited by 67
Borchard, G., Flühmann, B., & Mühlebach, S. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.08.009 · Cited by 66
Lee, E. S., Park, B. R., Kim, J. S., Choi, G. Y., Lee, J. J., & Lee, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.760444 · Cited by 65
Toblli, J. E., Cao, G., Oliveri, L. M., & Angerosa, M. (2012) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152812798889358 · Cited by 64
Hoff, C. M., Hansen, H. S., Overgaard, M., Grau, C., Johansen, J., Bentzen, J., & Overgaard, J. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.09.024 · Cited by 63
Musallam, K. M., Dahdaleh, F. S., Shamseddine, A. I., & Taher, A. T. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.09.008 · Cited by 63
Barosi, G., Bosi, A., Abbracchio, M. P., Danesi, R., Genazzani, A. A., Corradini, P., Pane, F., & Tura, S. (2011) · Haematologica · doi:10.3324/haematol.2011.041210 · Cited by 63
Effects of intravenous iron on mononuclear cells during the haemodialysis session
Martín‐Malo, A., Merino, A. M., Carracedo, J., Alvarez-Lara, M. A., Ojeda, R., Soriano, S., Crespo, R., Ramı́rez, R., & Aljama, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr711 · Cited by 62
Engert, A., Josting, A., Haverkamp, H., Villalobos, M., Lohri, A., Sökler, M., Zijlstra, J. M., Sturm, I., Topp, M. S., Rank, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1835 · Cited by 59
Vansteenkiste, J., Glaspy, J. A., Henry, D. H., Ludwig, H., Pirker, R., Tomita, D. K., Collins, H., & Crawford, J. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.015 · Cited by 59
Self-citationMundle, S. D., Lefèbvre, P., Vekeman, F., Duh, M. S., Rastogi, R., & Moyo, V. M. (2009) · Cancer · doi:10.1002/cncr.24090 · Cited by 57
Erythropoietin receptor contributes to melanoma cell survival in vivo
Kumar, S. M., Zhang, G., Bastian, B. C., Arcasoy, M. O., Karande, P., Pushparajan, A., Ács, G., & Xu, X. (2011) · Oncogene · doi:10.1038/onc.2011.366 · Cited by 57
Progress in detecting cell-surface protein receptors: the erythropoietin receptor example
Elliott, S., Sinclair, A. M., Collins, H., Rice, L. L., & JELKMANN, W. E. B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1947-2 · Cited by 55
Stein, J. M., Dignass, A. U., & Chow, K. U. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.651527 · Cited by 53
Aapro, M., Osterwalder, B., Scherhag, A. W., & Burger, H.-U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605255 · Cited by 52
Self-citationInfluence of Iron on In Vivo Proliferation and Lethality of L1210 Cells
Bergeron, R. J., Streiff, R. R., & Elliott, G. T. (1985) · Journal of Nutrition · doi:10.1093/jn/115.3.369 · Cited by 48
Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes
Santini, V. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s3-35 · Cited by 48
Self-citationSupportive Treatments for Patients with Cancer
Jordan, K., Feyer, P. C., Höller, U., Link, H., Wormann, B. J., & Jahn, F. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0481 · Cited by 47
Self-citationEpo Receptors Are Not Detectable in Primary Human Tumor Tissue Samples
Elliott, S., Swift, S. E., Busse, L. A., Scully, S. A., Van, G. Y., Rossi, J., & Johnson, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068083 · Cited by 43
Baldamus, C. A., Krivoshiev, S., Wolf-Pflugmann, M., Siebert-Weigel, M., Koytchev, R., & Bronn, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0111-1 · Cited by 42
Toledano, A., Luporsi, É., Morère, J., Scotté, F., Laribi, K., Barrière, J., Huot-Marchand, P., Duvillié, L., Concas, V., & Bugat, R. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2728-3 · Cited by 42
Hedenus, M., Karlsson, T., Ludwig, H., Rzychon, B., Felder, M., Roubert, B., & Birgegård, G. (2014) · Medical Oncology · doi:10.1007/s12032-014-0302-3 · Cited by 41
Self-citationSmith, S. W., Sato, M., Gore, S. D., Baer, M. R., Xu, K., McNally, D. L., & Davidoff, A. J. (2011) · Haematologica · doi:10.3324/haematol.2011.051755 · Cited by 41
Thrombotic Complications of Myeloma Therapy
Zonder, J. A. (2006) · Hematology · doi:10.1182/asheducation-2006.1.348 · Cited by 41
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig, H., Aapro, M., Bokemeyer, C., Glaspy, J. A., Hedenus, M., Littlewood, T. J., Österborg, A., Rzychon, B., Mitchell, D., & Beguin, Y. P. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2189-0 · Cited by 39
Self-citationImpact of illegal trade on the quality of epoetin alfa in Thailand
Fotiou, F., Aravind, S., Wang, P., & Nerapusee, O. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.014 · Cited by 39
A new concept for the differential diagnosis and therapy of anaemia in cancer patients
Steinmetz, H. T., Tsamaloukas, A. G., Schmitz, S. H., Wiegand, J., Rohrberg, R., Eggert, J., Breuer, F., Tessen, H.-W., Eustermann, H., & Thomas, L. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0812-2 · Cited by 38
Bailie, G. R., Hörl, W. H., & Verhoef, J. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296198 · Cited by 38
Xu, Q., Zhu, M., Yang, T., Xu, F., Liu, Y., & Chen, Y. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.022 · Cited by 33
Wu, P., Zhang, N., Wang, X., Zhang, C., Li, T., Ning, X., & Gong, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045122 · Cited by 30
Kerkhofs, L. G. M., Boschetti, G., Lugini, A., Stănculeanu, D. L., & Palomo, A. G. (2012) · Future Oncology · doi:10.2217/fon.12.39 · Cited by 26
Die individualisierte Riskoeinschätzung und Therapieplanung bei myelodysplastischen Syndromen
Stauder, R., Wimazal, F., Nösslinger, T., Krieger, O., Sperr, W. R., Sill, H., Pfeilstöcker, M., & Valent, P. (2008) · Wiener klinische Wochenschrift · doi:10.1007/s00508-008-1058-6 · Cited by 11
Self-citation
Research works printed but not linked: 24
- Delarue, 2013, Iron parameters and relation to prognosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study, Blood, 122
- Hudis, 2004, rHuEPO and treatment outcomes: the clinical experience, Oncologist, 9, 55, 10.1634/theoncologist.9-90005-55 · doi:10.1634/theoncologist.9-90005-55
- Aapro, 2016, Practical recommendations for the treatment of anemia in cancer patients, Malignant Tumors, 4, 368
- Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, Br J Haematol, 122, 394, 10.1046/j.1365-2141.2003.04448.x · doi:10.1046/j.1365-2141.2003.04448.x
- Aapro, 2009, An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology, Oncologist, 14, 1, 10.1634/theoncologist.2009-S1-1 · doi:10.1634/theoncologist.2009-s1-1
- Cazzola, 1995, Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response, Blood, 86, 4446, 10.1182/blood.V86.12.4446.bloodjournal86124446 · DOI
- Moebus, 2013, Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial, J Nat Cancer Inst, 105, 1018, 10.1093/jnci/djt145 · doi:10.1093/jnci/djt145
- Aapro, 2015, Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis, Ann Oncol, 26, 688, 10.1093/annonc/mdu579 · doi:10.1093/annonc/mdu579
- Galli, 2004, Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma, Haematologica, 89, 1141
- Hastka, 1994, Central role of zinc protoporphyrin in staging iron deficiency, Clin Chem, 40, 768, 10.1093/clinchem/40.5.768 · doi:10.1093/clinchem/40.5.768
- Aapro, 2011, Too-low iron doses and too many dropouts in negative iron trial?, J Clin Oncol, 29, e525, 10.1200/JCO.2011.35.3219 · doi:10.1200/jco.2011.35.3219
- Jaspers, 2015, Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation, Am J Hematol, 90, e133, 10.1002/ajh.24013 · doi:10.1002/ajh.24013
- Rezazadeh, 2005, Evidence that iron overload plus croton oil induce skin tumours in mice, Hum Exp Toxicol, 24, 409, 10.1191/0960327105ht544oa · DOI
- Link, 2013, Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany, Onkologie, 36, 266
- Osterborg, 1998, Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?, Med Oncol, 15, S47
- Upile, 2009, Blood product transfusion and cancer prognosis, Clin Adv Hematol Oncol, 7, 656
- Halabi, 2013, Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis, Am J Surg, 206, 1024, 10.1016/j.amjsurg.2013.10.001 · doi:10.1016/j.amjsurg.2013.10.001
- Carson, 2014, Should we universally adopt a restrictive approach to blood transfusion? It's all about the number, Am J Med, 127, 103, 10.1016/j.amjmed.2013.10.026 · doi:10.1016/j.amjmed.2013.10.026
- Sanon, 2011, Peripheral arterial ischemic events in cancer patients, Vasc Med, 16, 119, 10.1177/1358863X10388346 · doi:10.1177/1358863x10388346
- Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744 · doi:10.1182/blood-2012-04-425744
- Ferro, 2012, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies, Kidney Int, 81, 1273, 10.1038/ki.2012.22 · doi:10.1038/ki.2012.22
- Krivoshiev, 2008, Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia, Curr Med Res Opin, 24, 1407, 10.1185/030079908X297402 · doi:10.1185/030079908x297402
- Haag-Weber, 2009, Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis, Clin Nephrol, 72, 380
- Weigang-Köhler, 2009, HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours, Oncol Res Treat, 32, 168, 10.1159/000200783 · doi:10.1159/000200783
Cited by
Cancer-Related Fatigue: Causes and Current Treatment Options
Thong, M. S. Y., van Noorden, C. J. F., Steindorf, K., & Arndt, V. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0707-5 · Cited by 438
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00382-0 · Cited by 326
Iron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation
Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M. (2018) · Pharmaceuticals · doi:10.3390/ph11040097 · Cited by 132
Metadata
- Authors
- Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., & Herrstedt, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Issue
- Suppl 4
- Pages
- iv96-iv110
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2894700795
- Cited by
- 288
- References
- 136
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 463 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.